Scilex Holding Company Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Scilex Holding Company (SCLX) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $4.39 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-14
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $4.39M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $6.59M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.02M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.04M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $4.39M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $6.59M 10-Q · filed 2026-05-20 |
| 2025-09-30 | $1.02M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $2.04M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $3.00M 10-Q · filed 2025-05-14 |
| 2024-09-30 | $1.00M 10-Q · filed 2025-01-17 |
| 2024-06-30 | $2.00M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $3.00M 10-Q · filed 2024-05-13 |
| 2023-09-30 | $1.03M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $2.05M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $3.08M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |